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metabolic maps and lending clues to mechanisms of bioactivation. Thus, the LC–MS-based
metabolomic approach is a powerful tool for proﬁling of drug metabolism and bioactivation.
& 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.edica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
itute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
588 1749.
Xiaochao Ma).
LC–MS-based metabolomics in drug metabolism proﬁling 1191. Introduction
Systematic investigation of drug metabolism has become an
indispensable part of drug development, clinical therapy, and
mechanistic study of drug-induced toxicity. Most drugs are
transformed into more polar and stable metabolites by hepatic
enzymes which facilitates their elimination from the body.
Reactive metabolites can be generated during the process of drug
metabolism that can covalently bind to protein, RNA and DNA,
resulting in toxicity1,2. Identiﬁcation of reactive metabolites helps
medicinal chemists minimize the formation of reactive metabolites
by optimizing the structure of the parent drug3,4. This knowledge
also provides valuable information on the mechanism of drug-
induced toxicity5,6. Retrometabolic drug design is mainly based on
drug metabolism.7 For a drug with a low bioavailability because
of extensive ﬁrst-pass effect, a metabolism-based structural mod-
iﬁcation will block the major metabolic pathway of the drug and
thus improve its bioavailability7,8.
Metabolomics is the global analysis of small molecule
metabolites in a biological sample by integration of state-of-
the-art analytic tools and bioinformatics9,10. At present, nuclear
magnetic resonance (NMR) spectrometry11,12 and mass spec-
trometry (MS)13–16 as analytical platforms are used in metabo-
lomic studies. The advantages and disadvantages of NMR and
MS have been delineated in recent reviews17,18. Brieﬂy, NMR-
based metabolomics is advantaged in quantitation and com-
prehensive coverage of chemical species, but suffers from low
sensitivity. In contrast, MS-based metabolomics possesses high
sensitivity, but suffers from imprecise identiﬁcation of com-
pound structures and lack of precise quantitation, especially
when an internal standard is not available. Multivariate dataFigure 1 The overall strategy for studying drug metabolism
using a metabolomic approach. The mixture of a drug and its
metabolites is analyzed by LC–MS and the data are acquired and
processed to generate a data matrix that is further analyzed by
multivariate data analysis (MDA) to screen drug metabolites. For
reactive metabolites, trapping reagents are needed because of their
unstable properties.analysis (MDA) is an essential component in metabolomic
analysis to assist in the extraction of valuable information from
large datasets19. MDA is classiﬁed into unsupervised and
supervised methods. Principal component analysis (PCA) is
the most popular unsupervised method to analyze multivariate
data and rapidly provide an overview of the information hidden
in the data. The supervised MDA methods include partial least
squares, orthogonal partial least squares, and orthogonal
partial least squares-discriminant analysis (OPLS-DA)20,21.
OPLS-DA is designed for modeling two classes of data to
increase the class separation, simplify interpretation, and ﬁnd
potential biomarkers. Metabolomics has been widely used in
various ﬁelds, such as nutrition22, plant biochemistry and
agriculture23, toxicology24, cell and molecular biology25. Meta-
bolomics has also been adopted in drug metabolism and used
for screening of stable metabolites and reactive metabolites26–28.
In this report, the implications of the metabolomic
approach in proﬁling of drug metabolism and bioactivation
are summarized and discussed (Fig. 1). Brieﬂy, drug metabo-
lism can produce stable metabolites and reactive metabolites.
The mixture of metabolites and the parent drug can be
analyzed by liquid chromatography-mass spectrometry (LC–
MS) to generate a data matrix that can be further analyzed by
MDA to screen drug metabolites. In some cases, trapping
reagents are required in the study of reactive metabolites
because of their unstable properties.2. An LC–MS-based metabolomic strategy
for studying drug metabolism
Although NMR-based metabolomics has been widely used in
metabolomic studies, MS-based metabolomics is increasingly
employed because of its high resolution and sensitivity as well
as the more wide availability of instruments. Gas chromato-
graphy mass spectrometry (GC–MS) and LC–MS are the
prevailing analytic instruments in MS-based metabolomic
studies. Compared with GC–MS, the advantage of LC–MSFigure 2 A schematic for identiﬁcation of drug metabolites
in vivo using a metabolomic approach. Urine and/or feces samples
can be analyzed using LC–MS to generate a data matrix. The data
matrix is then subjected to multivariate data analysis (MDA) to
screen drug metabolites.
Feng Li et al.120is that no chemical derivatization is required and the run times
are faster resulting in high throughput capabilities29. With the
advent of ultra-performance liquid chromatography (UPLC)
and highly accurate MS, the application of UPLC–MS has
dramatically increased in metabolomic studies.2.1. Proﬁling of stable metabolites
2.1.1. Proﬁling of stable metabolites in vivo
Metabolite identiﬁcation in vivo is challenging, since thou-
sands of chemical species exist in biosamples, such as urine
and serum. Radiotracing is a commonly used method for
identifying the drug metabolites in vivo. However, this method
strongly depends on the availability of the radiolabelled
compounds that are sometimes difﬁcult and expensive to
synthesize and require containment facilities for use. In
addition, labeled compounds can be metabolized at differentFigure 3 Metabolomic analysis of ATV metabolism in mice.
Wild-type (WT) mice were treated with vehicle or 50 mg/kg ATV
(po, n¼4). Urine and feces were collected (0–18 h) for metabolite
analysis. (A) Separation of control and ATV-treated mouse feces
in a PCA scores plot. The t[1] and t[2] values represent the score
of each sample in principal component 1 and 2, respectively.
(B) Loading S-plot generated by OPLS-DA analysis of a meta-
bolome in ATV-treated mouse feces. The X-axis is a measure of
the relative abundance of ions and the Y-axis is a measure of the
correlation of each ion to the model. These loading plots represent
the relationship between variables (ions) in relation to the ﬁrst and
second components present in the PCA scores plot. Overall,
eighteen ATV metabolites were identiﬁed, including ﬁve pre-
viously reported metabolites34 and thirteen novel metabolites.35rates by enzymes30. Accompanying the advent of new technol-
ogy associated with MS, several MS-based methods have been
developed, such as multiple reaction monitoring (MRM) and
mass defect ﬁltering (MDF) for screening and characterizing
drug metabolites31,32. While all these methods are effective,
they are inherently biased. These methods will miss the
unexpected and uncommon metabolites.
Metabolomics is an unbiased approach for metabolite
identiﬁcation29. For in vivo studies, biological samples (urine
and/or feces) are required from both the vehicle-treated and
drug-treated groups (Fig. 2). These samples can be analyzed
using LC–MS. Subsequently, chromatographic and spectral
data are collected and processed using methods such as
centroiding, deisotoping, ﬁltering, and peak recognition, to
generate a data matrix including sample identity, ion identity
and ion abundance. The data matrix is then subjected to PCA
and OPLS-DA analyses29,33. Because the target drug and its
metabolites only exist in the drug-treated group, they will
highly contribute to the separation of the vehicle and drug-
treated groups in the S-plot generated from OPLS-DA
analysis (Fig. 3). Therefore, the metabolites can be readily
identiﬁed from a large dataset.
One example of the value of metabolomics is the analysis of
atazanavir (ATV) metabolism. ATV is an anti-HIV drug of the
protease inhibitor class. In a previous study, ﬁve ATV metabolites
were elucidated34. ATV metabolism was re-examined in mice
using a metabolomic approach35. PCA analysis of feces revealed
two clusters corresponding to the control and ATV-treated groups
(Fig. 3A). The S-plot generated from OPLS-DA displayed the
ions contributing to the group separation in the feces (Fig. 3B).
The top ranking ions were identiﬁed as ATV and its metabolites,
including two N-dealkylated metabolites, four monohydroxylated
metabolites, two monohydroxylated and monodehydrogenated
metabolites, two dihydroxylated metabolites, three dihydroxylated
and monodehydrogenated metabolites, two hydrolyzed metabo-
lites, one hydrazine, one aromatic aldehyde, and one a-hydro-
xyaldehyde. Overall, the metabolomic analysis extended the ATVFigure 4 A schematic for identiﬁcation of drug metabolites
in vitro using a metabolomic approach.
Figure 5 Metabolomic analysis of TPV metabolism in HLM. The incubation was conducted in phosphate-buffered saline (PBS, pH 7.4),
containing 50 mM TPV, HLM (1.0 mg/mL), and NADPH (1.0 mM) in a ﬁnal volume of 200 mL. The incubation without NADPH served
as control. All reactions were terminated by adding 200 mL of acetonitrile. The supernatants were injected into LC–MS for analysis.
(A) Separation of control and TPV analyte in a PCA scores plot. The t[1] and t[2] values represent the score of each sample in principal
component 1 and 2, respectively. (B) Loading S-plot generated by OPLS-DA analysis and marked metabolites. The X-axis is a measure of
the relative abundance of ions and the Y-axis is a measure of the correlation of each ion to the model. These loading plots represent the
relationship between variables (ions) in relation to the ﬁrst and second components present in the PCA scores plot. þNa, Sodium
adducts. (C) Metabolic map of TPV in HLM. Five metabolites were identiﬁed including one dehydrogenated metabolite (M1), three
monohydroxylated metabolites (M2, M3, and M4), and one depropylated metabolite (M5).
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Figure 6 Adduct formation of commonly encountered reactive metabolites and trapping reagents.
Feng Li et al.122metabolic map to ﬁve known and thirteen novel metabolites
(Fig. 3)35. A metabolomic approach has also been used in the
metabolism of aminoﬂavone28, arecoline and arecaidine36, mela-
tonin37, acetaminophen38, and cyclophosphamide39. In all of these
cases, large numbers of novel metabolites were uncovered. These
data suggest that a metabolomic approach is a powerful tool for
proﬁling of drug metabolites in vivo.Figure 7 A schematic for proﬁling of reactive metabolites using a
metabolomic approach.2.1.2. Proﬁling of stable metabolites in vitro
In vitro assays are convenient for studying drug metabolism. In
particular, liver microsomes, hepatocytes, and recombinant
human cytochrome 450s (CYPs) are commonly used in studying
drug metabolism in vitro40. A metabolomic strategy (Fig. 4) can
also be applied for in vitro studies of drug metabolism41–43.
Tipranavir (TPV) is a nonpeptidic protease inhibitor used for
the treatment of HIV infection. The metabolism of TPV in human
liver microsomes (HLM) was investigated using a metabolomic
approach41. TPV was incubated with HLM in the presence or
absence of the CYP cofactor NADPH. By using PCA analysis,
two groups were clearly separated in a scores plot (Fig. 5A) with
TPV metabolites as top ranking ions contributing to the groupseparation (Fig. 5B). Metabolomic analysis revealed ﬁve metabo-
lites in vitro, including dehydrogenated metabolite M1, monohy-
droxylated metabolites M2, M3, and M4, and depropylated
metabolite M5 (Fig. 5C). M5 was an uncommon metabolite
generated by CYP-mediated carbon-carbon bond cleavage, which
was not identiﬁed in previous studies on TPV metabolism44,45.
Figure 8 Metabolomic analysis of LPV bioactivation. Quadruplicate incubations were conducted in PBS (pH 7.4) containing LPV
(30 mM), HLM (1.0 mg/mL), with or without GSH (2.5 mM) or NADPH (1.0 mM). All samples were analyzed by UPLC-TOF MS.
(A) Separation of each incubation group in an OPLS-DA scores plot. The t[1]P and t[2]O values represent the score of each sample in
principal component 1 and 2, respectively. (B) Loading S-plot generated by OPLS-DA analysis. The X-axis is a measure of the relative
abundance of ions and the Y-axis is a measure of the correlation of each ion to the model. The top ranking ions are labeled. , in-source
fragment. (C) Twelve GSH-trapped reactive metabolites of LPV (I-XII) were identiﬁed. In addition, three aldehydes were noted.27 DMP:
2,6-dimethylphenol.
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is still not clear. These data indicate that a metabolomic approach
is an effective tool for identifying drug metabolites in vitro.2.2. Screening of reactive metabolites
Reactive metabolites can be generated in drug metabolism and
they are frequently associated with drug-induced toxicity. Ingeneral, reactive metabolites are classiﬁed into soft and hard
electrophiles (Fig. 6). Classic soft electrophiles include epoxides,
a,b-unsaturated carbonyls, quinones, quinone imines, quinone
methides, imine methide, isocyanate, isothiocynates, aziridi-
nium, and episulfonium. Aldehydes and iminium ions belong
to the group of hard electrophiles. Because most reactive
metabolites are unstable and cannot be detected directly,
trapping reagents are commonly used to identify reactive
metabolites. Glutathione (GSH) and its analogues are used to
Feng Li et al.124trap soft electrophiles46–49. For example, GSH can react with
epoxides to form stable thioalcohols. Hard electrophiles can be
trapped by semicarbazide, methoxylamine, or cyanide ions50–54.
For instance, semicarbazide can condense with the aldehydes to
generate stable hydrazones. Adducts of reactive metabolites and
trapping reagents are generally stable and detectable. However,
it is still challenging to separate these adducts from complex
biological matrixes.
The metabolomic approach, as an unbiased method, was
successfully used for the screening of trapped reactive meta-
bolites26. This strategy is illustrated in Fig. 7. Brieﬂy, a drug is
incubated with CYP and other enzymes. The incubation
groups without NADPH or trapping reagent serve as controls,
which are used to identify NADPH and trapping reagent-
dependent biomarkers of drug bioactivation. Bioactivation of
lopinavir (LPV), a HIV protease inhibitor, was examined
using GSH as a trapping reagent and analyzed by a metabo-
lomic approach27. PCA analysis revealed three clusters in a
scores plot (Fig. 8A), with the GSH adducts of LPV as the
major ions contributing to group separation (Fig. 8B). Over-
all, twelve GSH-trapped reactive metabolites of LPV were
identiﬁed (Fig. 8C). These data indicate that a metabolomic
approach is an ideal tool for the screening of trapped reactive
metabolites.3. Conclusion and perspectives
Compared to traditional methods, LC–MS-based metabolo-
mic strategy can provide more comprehensive proﬁle of both
regular and reactive metabolites, and thus is of great advan-
tage in drug metabolism. (1) This strategy is capable of
handling the large datasets generated from the biomatrix;
(2) it is indiscriminative in metabolite identiﬁcation; (3) it
provides a straightforward visualization of the metabolic
changes; (4) in many cases, the use of isotope-labeled com-
pounds is not necessary. Overall, LC–MS based metabolomics
is a powerful, effective, and unbiased tool for metabolic
proﬁling.
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